Cheminformatics and Structural Biology Analysis for Drug Discovery
Analyze compounds, fingerprints, scaffolds, ADMET-style properties, molecular similarity, protein structures, contacts, B-factors, SASA, and sequence or structure evidence.
Decision questions
What this solution is built to answer.
How similar are these compounds, scaffolds, or activity profiles?
What do ADMET-style properties or fingerprints suggest about a compound set?
What does a structure reveal about contacts, exposure, secondary structure, or flexibility?
Can molecular evidence feed target, indication, or competitive decisions?
Capabilities
What ARiDA can run for this use case.
RDKit cheminformatics for descriptors, fingerprints, scaffold analysis, similarity, MMP-style workflows, and ADMET-style screens.
ChEMBL and PubChem access paths for compound and activity context.
Biopython, biotite, ProDy, and py3Dmol for sequence and structure work.
Structural scripts for PDB info, contact maps, Ramachandran, B-factor, SASA, secondary structure, and superposition.
Pathway and enrichment workflows with GSEA, GO, KEGG/UniProt-style service access.
Workflow table
Named workflows and expected artifacts.
| Workflow | Role | Artifacts |
|---|---|---|
| cheminformatics | Compound and similarity analysis | Scaffold, property, fingerprint, diversity, MMP, ADMET-style outputs |
| structural-biology | Protein structure analysis | Contact maps, B-factor, SASA, secondary structure, superposition outputs |
| sequence-analysis / pathway-enrichment | Biological sequence and pathway interpretation | Alignment, enrichment, and pathway outputs |
Evidence inputs
Data sources, tools, and user context.
Outputs
What the workflow should leave behind.
Deliverables
Compound property and similarity tables.
Scaffold, fingerprint, diversity, and ADMET-style reports.
Protein structure visualizations and metrics.
Scientific evidence files for downstream strategy or diligence.
Proof points
The analysis environment includes RDKit, Biopython, PubChemPy, ChEMBL client, pathway tools, structure tools, and py3Dmol.
Structural-biology scripts are curated rather than invented per run.
Outputs can be combined with literature, trial, patent, and valuation lanes.
FAQ
Common evaluation questions.
Is this only for small molecule work?
Compound workflows are one part of the surface. Structural, sequence, pathway, and network analysis workflows also cover protein and biological evidence questions.
Can scientific outputs feed valuation or strategy?
Yes. Scientific evidence can feed probability assumptions, indication scoring, competitive differentiation, diligence caveats, and board-level recommendations.
Related solutions
Biomedical Data Analysis
Analyze biomedical files, tables, model outputs, and database extracts with Python, SQL, statistics, machine learning workflows, and durable artifacts.
Indication Expansion
Scan, assess, and sequence indication opportunities with scientific rationale, clinical feasibility, competitive density, IP context, market structure, and valuation logic.
Systematic Review
Run PRISMA-style biomedical literature reviews with PubMed and PMC search lanes, screening logic, evidence tables, certainty summaries, and durable review artifacts.
Related reading
How ARiDA Combines Live Web, Biomedical Databases, and Code Execution
Biotech research needs current signal, domain-native evidence, and computation in the same loop. Remove one layer and the output gets weaker.
What an AI Research System Needs to Be Useful in Pharma
Pharma teams need software that fits the realities of evidence, review, and organizational decision-making.
Designing AI Research Systems for Biotech: Tools, Workflows, and Durable State
Biotech research systems need workflow structure, specialist lanes, files, and repeatable execution paths around the model.